Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial

BACKGROUND: Neoadjuvant chemotherapy followed by surgery is the standard of care for UK patients with locally advanced resectable oesophageal carcinoma (OeC). However, not all patients benefit from multimodal treatment and there is a clinical need for biomarkers which can identify chemotherapy respo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Hale, Matthew D., Nankivell, Matthew, Hutchins, Gordon G., Stenning, Sally P., Langley, Ruth E., Mueller, Wolfram, West, Nicholas P., Wright, Alexander I., Treanor, Darren, Hewitt, Lindsay C., Allum, William H., Cunningham, David, Hayden, Jeremy D., Grabsch, Heike I.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363605/
https://ncbi.nlm.nih.gov/pubmed/27769054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12723
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados